Xenon Pharmaceuticals XENE Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's pre-tax income?
- Xenon Pharmaceuticals (XENE) reported pre-tax income of -$104.87M in Q1 2026.
- How has Xenon Pharmaceuticals's pre-tax income changed year-over-year?
- Xenon Pharmaceuticals's pre-tax income decreased by 62.3% year-over-year, from -$64.62M to -$104.87M.
- What is the long-term trend for Xenon Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's pre-tax income has grown at a 44.6% compound annual growth rate (CAGR), from -$78.89M to -$344.89M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.